Notably, this was not the case for any of the mutations in the key breast cancer genes TP53, ATM, and CDH1 emerging during docetaxel treatment (see above), indicating that these variants may have been acquired during docetaxel. The gene discussed is CDH1; the disease is breast carcinoma.